Here at OutsourcingPharma, we put our audience at the heart of what we do. For many years, we have provided our readers with a 360-degree view of the pharma landscape and our editorial standards remain unsurpassed.
Finch Therapeutics announced its shock decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) yesterday (Jan 25) saying instead it will focus on ‘realizing the value of its intellectual property estate and...
A Florida doctor has been sent to prison after submitting a false affidavit claiming she had screened children in a clinical study looking at the effectiveness of drugs given to children with asthma when she had not.
The US Food and Drug Administration (FDA) has approved AstraZeneca’s asthma treatment, Airsupra after positive results from a global phase 3 clinical trial.
The not-for-profit organization published its fair inclusion score to measure and rank pharmaceutical companies on their inclusion of women, older adults, and racial and ethnic minoritized patients.
The cryptocurrency space suffered through a torrid, scandal-marked 2022 but there remains interest in using the blockchain infrastructure that underpins the sector in other contexts. In a recent review of the potential of the blockchain in healthcare,...
Turbine will provide its machine learning platform to better understand which cancer types and patient population stand to benefit most from treatment by Cancer Research’s drug candidate.
On Friday (Jan 6), the US Food and Drink Administration (FDA) granted a licence for another anti-amyloid drug – lecanemab – to treat Alzheimer’s disease.
As the year draws to a close, Outsourcing-Pharma caught up with some senior executives for a three-part series looking back on an eventful 2022, and look ahead to 2023.
Pfizer receives additional orders for its COVID-19 treatment, after US requests more doses, and several Chinese companies are also reported to have begun selling the product.
As the year draws to a close, Outsourcing-Pharma caught up with some senior executives for a three-part series looking back on an eventful 2022, and look ahead to 2023.
As the year draws to a close, Outsourcing-Pharma caught up with some senior executives for a three-part series looking back on an eventful 2022, and look ahead to 2023.
Millstone Medical Outsourcing is keeping up the pace of its deal-driven expansion strategy by closing the takeover of regulatory testing services provider Ethide Laboratories.
Emergent’s application for its Narcan product to be sold OTC for the treatment of opioid overdose has been accepted by the US FDA and provided priority review.
CordenPharma joins global science initiative SBTi and announces commitment to ambitious reduction in greenhouse gas emissions in alignment with the Paris agreement.
The CRO focuses its services towards biotechs by stating that they are cheaper and more efficient compared to rivals, and it was this principle that drew in General Catalyst to provide investment.
ALS genetic carrier finds value in EverythingALS study leveraging digital biomarkers as a means to create tools for early detection of ALS and potentially other neurological diseases.
First ever longtudinal study from ALS non-profit focuses on finding digital biomarkers using IBM Research’s proprietary AI. The study leverages audiovisual samples from participants with ALS, genetic carriers, and caregivers.
For its two lead oncology programs, the company will pursue “market-based pricing”, moving away from plans to “dramatically lower prices” for treatments.
The two companies will combine real-world datasets to better understand marketing treatment with Bristol Myers Squibb’s drug in a post-marketing setting.
Icon is looking to its Accellacare global clinical research network to mitigate the effect of site staffing issues on the speed at which trials are executed and revenues are realized.
In-home nurse visits, using familiar mobile devices to upload health data, and telemedicine calls with a doctor are the elements of decentralized clinical trials with the biggest positive impact on participation in future studies, according to a survey.
CVS Health and Walgreens announce that they will settle all opioid claims against them by US states, while it is reported that Walmart will do the same.
